Danish Registry Data Show Rising ADHD Medication Use and Sex Convergence

Pharmacological intervention remains a cornerstone of multimodal management for attention deficit hyperactivity disorder (ADHD), with stimulants and non-stimulants significantly reducing core symptoms and improving quality of life in pediatric populations [1, 2, 3]. Despite the established efficacy of these agents, clinicians face persistent challenges regarding long-term treatment adherence, as data indicate that only 22.9% of youth maintain good adherence at a 12 month follow-up [4]. Cardiovascular safety also remains a primary monitoring concern, although meta-analytic data of nearly four million participants suggest no statistically significant association between ADHD medications and serious cardiovascular events across age groups [5]. Furthermore, rising diagnosis rates among female patients have introduced new complexities in managing ADHD across the lifespan, including considerations for reproductive health and the prevalence of medication exposure during pregnancy [6]. While current treatments effectively mitigate functional impairments, they rarely normalize long-term outcomes to the level of neurotypical peers, necessitating a deeper understanding of how prescribing patterns are shifting in real-world clinical practice [7]. A comprehensive analysis of Danish national registry data from 2010 to 2023 now provides a detailed look at how these treatment dynamics have transformed over the last decade.